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INTRODUCTION  
Maintaining intravascular volume and blood pressure is essentially equivalent to 
maintaining life. Blood pressure is a critical vital sign that organisms try to preserve at 
all cost. The two central components of blood pressure is maintaining vascular tone and 
maintaining intravascular volume.  While regulation of the fluid status has been studied 
and explored in the last century the assessment part of this seems to have been a more 
difficult element of fluid status maintenance.  
There are physiological mechanisms in the kidney, carotid body and the heart among 
other sites of the body where this process is done. We will focus on how clinicians can 
assess the fluid status in the most vulnerable patient population, those with renal 
dysfunction. We will therefore investigate how best to assess fluid status in the End 
Stage Renal Disease (ESRD) population and we will offer two options for this. 
The clinical task of accurately ascertaining patients’ volume status seems quite easy. 
Physical exam is the part of the medical evaluation that may be most problematic, 
however. Many studies found it difficult to accurately ascertain fluid status by physical 
exam more accurately than 49%, some found the accuracy that pulmonary crackles had 
a sensitivity of 56%, S3 third heart sound 20%, jugular venous distention 39% and 
edema 67%.  Others found that sensitivities of peripheral edema detecting fluid overload 
ranged from 1-10% while lung crackles indicated instrument-detected pulmonary fluid 
overload 9-27% depending whether the pulmonary edema was deemed mild, moderate 
or severe. It is thus clear that physical exam in the dialysis patient population was 
similarly unable to give appropriate assessment for fluid status. 
An alternative to physical exam-assessed fluid status is the use of a biomarker B-type 
Natriuretic Peptide (BNP) or a device such as the bioimpedance apparatus, BCM. 
Because cardiac hormones are degraded through the neutral endopeptidase (NEP) and 
NEP is expressed particularly abundantly expressed in the kidney its blood levels are 
higher in renal failure. Another method to assess fluid excess or perhaps deficit is 
through a device whose physics of BCM is based on the conductivity of various body 
compartments at different rates and resistance values. BCM “enables clear separation 
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between extracellular and intracellular water by the extremely wide range of 
measurement frequencies”. 
OBJECTIVES 
The dissertation will examine and present studies to the following question: What is the 
clinical importance of measuring fluid excess in the dialysis population?  
The hypothesis of the dissertation is thus to show that using actual fluid space 
measurements by BNP or BCM improves care of the dialysis patient. Further, fluid 
management based on measured fluid spaces will decrease fluid overload, blood 
pressure and polypharmacy. 
METHODS 
Most of the studies discussed here are observational and cross sectional studies that 
entail two populations. Those patients whose fluid status had been measured by BNP 
are those who live in the North West Louisiana area of attrition, mostly elderly African 
Americans in the Veterans’ Affairs Medical Center. 
In a prospective observational study of a sub-cohort of 19 consecutively admitted 
veteran patients (of a cohort of 97 dialysis patients) acutely hospitalized, needed acute 
dialysis. Their indications for hospital admission varied and their symptoms were often 
unrelated to volume overload. After conventional hemodialysis was started in the 
hospital, ultrafiltration (UF) was commenced based on the admission BNP value. The 
UF was targeted to achieve a BNP goal of 500 pg⁄mL. … Since the target BNP was 500 
pg⁄mL, patients were deemed volume-overloaded if the BNP was >500 pg⁄mL.”  
The patient population of studies we performed using the bioimpedance was decidedly 
different from that of the BNP studies previously described. This was an East European 
population of all White people in Budapest, Hungary at Semmelweis University in a 
single chronic dialysis facility operated by a for-profit chain provider (Fresenius 
Medical Care) as a contractor for the universal health care system paid by a single, state 
payer. Patients were treated at this facility from a single territory of no more than 50 
miles radius and were all provided free transportation to and from the dialysis facility. 
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RESULTS 
The ultrafiltration treatment protocol that continued fluid removal targeting a BNP value 
of 500 pg/mL made a very significant change in every measure we set out to improve. 
As a result of BNP-directed ultrafiltration body weight came down by 10.8 kg on the 
average and blood pressure decreased very significantly. Importantly, polypharmacy 
also decresedd by an average of 1.5 antihypertensive medication as well as  blood 
pressure also decreased: the systolic (by 21.5 mmHg) and diastolic readings (by 11.7 
mmHg) and mean arterial pressure by 12.5 mmHg.  
The patient population in Hungary for the bioimpedance studies had a mean vintage of 
66.5 ±57.1 months (range, 2–312 months) and a residual urine output of 442 ±521 
mL/day. “We found a significant correlation between OH and systolic blood pressure (r 
= 0.39; p = 0.0006) with each liter of OH generating 3.6 mm Hg. There was a positive 
correlation between the number of antihypertensive medications and the degree of OH 
that held true even when those patients with no blood pressure medications and those 
with five or more medications were excluded (r = 0.33; p = 0.047).” 
 
Figure 1. The number of antihypertensive medications and overhydration 
The number of antihypertensive medications has a strong relation with the degree of 
overhydration. n = 76, p <0.0001, r = 0.54  
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Additionally, the use of diuretics in dialysis patients does not seem to prevent fluid 
excess, in the presence of diuretics D (+), the degree of overhydration is significantly 
greater than in its absence D (-). p = 0.003. 
In a study where we compared BNP values and BCM measurements we found that there 
was a strong correlation between the two types of measurements. “Our data analysis 
included an evaluation of correspondence between the two methods, BNP values or 
OH%. We found that the linear regression analysis describing this relationship could be 
expressed with the equation of y = 209.83x - 1133.4 (r = 0.6996)”. “The ROC revealed 
a significant correspondence, with the AUC 0.885 for the BNP when the OH% was set 
to 15% of OH or greater.” 
 
Figure 2. “Area under the curve (AUC) for the receiver operating characteristic (ROC) 
curve for the BNP when the discriminating threshold between overhydration and 
normohydration is used as 15% of the extracellular water.” 
Fluid excess has been demonstrated to increase mortality in the dialysis population. In 
a landmark study Wizeman and co-workers showed that a volume overloaded state by 
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more than 15% of the extracellular volume increased mortality significantly. At the 
same time hypertension, just as in many other studies, was not directly related to 
mortality, HR: 0.986 (90% CI: 0.979-0.995 p = 0.014); hypertension in fact seems to 
provide a certain degree of protection… Additionally, a Turkish study found that a strict 
fluid or volume control will improve survival. Thus the mandate of driving the 
ultrafiltration by some objective measurement rather than physical exam alone is strong. 
Ozkahya also showed that blood pressure can significantly be improved all the while 
the number of antihypertensive medications are decreased provided the intravascular 
fluid status is improved by decreasing it according to some kind of objective guide. 
As a response that clinicians need to guide their management of hypertension and fluid 
status based on objective measurements were the studies presented before. The 
underlying problem is that physical exam is just simply not objective enough and simply 
unable to assess a patient’s fluid status enough to safely guide therapy. Physical exam 
when compared with an objective measurement do not measure up. “Lung congestion 
by crackles, edema, or a combination thereof poorly reflected the severity of congestion 
as detected by ultrasound B lines” or when compared to BNP measurements. 
What the presented papers and clinical studies using BNP or BCM have shown is an 
alternative to “driving blindly”.  There is no reason why biomarkers such as BNP should 
not be used in the regular clinical practice. In our study where we directed our UF 
procedure according to the BNP values of acute hospitalized, chronic dialysis patients 
we demonstrated that this method was clinically usable and applicable but even more 
importantly, it improved care. Relying solely on physical exam in our BNP study of 
hospitalized patients would have missed 50% of the volume overload. Thus physical 
assessment is as good as a coin toss!   
The third benefit of BNP directed ultrafiltration is the improvement of blood pressure 
control. The above article has demonstrated that removal of fluid will decrease blood 
pressure and discontinuation of antihypertensive medications become a possibility 
Polypharmacy, is dangerous not only because of the financial burden it involves but 
firstly because of the drug-drug interactions and the side-effect profiles that patients 
accumulate when taking more and more medications. Pill burden is another concern as 
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that is a known risk for patient non-adherence. A DOPPS study has demonstrated that 
taking too many pills will decrease compliance with phosphate binders. Taking 
phosphate binders is critically important, dialysis patients who use phosphate binders 
have a survival advantage over those who do not. The clinical benefits of blood pressure 
control in dialysis patients with antihypertensive medications is a matter of controversy. 
The idea of decreasing blood pressure is in the hopes to decrease mortality, cardiac 
events or stroke. This, among dialysis patients, however, has not been demonstrated so 
clearly by the literature. It is well known that good dialysis, done over long hours and 
aiming to achieve dry weight can achieve both a good blood pressure control and good 
survival, with a very small amount of antihypertensive medications.  
In a cross sectional study in a North-West Louisiana chronic dialysis cohort we counted 
how many antihypertensive medications our patients took without change in dose or 
new prescription for at least 2 months and compared that to their actual pre-dialysis 
blood pressures. We found that the more medications patients received the higher their 
blood pressure ended up being.  
 
Figure 3. Mean blood pressures grouped according to the number of medications 
“Mean blood pressures (BPs) grouped according to the number of antihypertensive 
medications. SBP, systolic BP; MAP, mean arterial pressure; DBP, diastolic BP”  
The relationship of hypertension, antihypertensive medications and outcome in dialysis 
patients may be explained by all the above investigations presented and therein lies the 
clinical utility of objective fluid assessment, by any method. We have shown that 
escalating antihypertensive medications, giving more and more medications to dialysis 
patients in fact does not improve their blood pressure control, or is not associated with 
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a better blood pressure control. We have, however, demonstrated fluid excess is 
associated with higher blood pressure and higher number of antihypertensive 
medications. Furthermore, fluid removal will decrease blood pressure and 
polypharmacy.  
Successful luid removal may eliminate the excess mortality risk described by Wizeman. 
Onofriescu has also shown that patients whose dry weight was managed with 
bioimpedance versus those whose dry weight was managed based on clinical judgement 
only – or any other objective measure of fluid status – had better survival. 
CONCLUSION 
What this dissertation has done is the integration of the previously proposed method of 
blood pressure control in dialysis patients and demonstrating in clinical practice how it 
can be done successfully. These studies have demonstrated that the safe way to go from 
polypharmacy and volume overload is to slowly decrease patients’ weight while 
decreasing the antihypertensive medication burden. This can be done in a safe way by 
continuously monitoring their volume status by the use of BNP or BCM — “turn the 
lights on when driving at night”. These clinical studies have all lined up in a string of 
idea that blood pressure control ought to be done not by medications but by eliminating 
the cause of hypertension. We should treat hypertension with minimal antihypertensive 
drugs in the dialysis population so that we can eliminate the greater mortality risk factor: 
volume overload. We ought to use one of these instruments to control fluid status safely. 
For the first time we demonstrated that BNP or BCM-directed fluid control actually 
improves care!  
The conclusions therefore include that fluid overload can be safely decreased when 
objective measurements guide therapy. Polypharmacy can be improved with BNP- or 
BCM- directed ultrafiltration and an excessive number of antihypertensive medications 
impede volume control. 
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